Sinovac Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
Sinovac Biotech Ltd. (Beijing, China), a developer and provider of vaccines, has executed a joint venture agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian).
Sinovac Biotech Ltd. (Beijing, China), a developer and provider of vaccines, has executed a joint venture agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The joint venture will research, develop, produce, and commercialize vaccines for human use. Sinovac will contribute its expertise and experience in developing and commercializing vaccines; the other party will bring its land use rights, manufacturing facilities, and established operating infrastructure.
Sinovac Dalian, headquartered in Dalian, Liaoning Province, will occupy a total area of approximately 1,000,000 square feet. The campus currently contains two vaccine production lines—one for the Vero cell cultured vaccines and one for live attenuated vaccines—and has capacity to house approximately six different production lines. In addition, the headquarters features quality assurance and quality control facilities, a research laboratory, an office building, and a warehouse.
Sinovac Dalian's development pipeline is expected to comprise vaccines for rabies, mumps, varicella, and rubella. The facility has a designed annual manufacturing capacity of 20 million doses of Vero cell cultured vaccines and 20 million doses of live attenuated vaccines.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
